Actively Recruiting
Radiotherapy to All Residual Lesions After Chemoimmunotherapy
Led by Anhui Provincial Hospital · Updated on 2024-08-09
150
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Extensive-stage small-cell lung cancer is a lethal malignancy with an extremely poor prognosis. First-line chemotherapy could only achieve an overall survival of approximately 10 months. CREST study demonstrated that the addition of thoracic radiotherapy to the patients who responded to chemotherapy could increase the 2-year survival rate from 3% to 13%. CASPIAN and IMpower 133 trials have established the standard modality of first-line chemoimmunotherapy for extensive-stage small-cell lung cancer and prolonged the overall survival to 13 months. Both the addition of thoracic radiotherapy and immunotherapy to chemotherapy were able to improve the survival. Recently, several retrospective studies have demonstrated the effectiveness and safety of the combination of thoracic radiotherapy and chemoimmunotherapy. In a prospective study, 4-6 cycles of first-line chemotherapy with Adebrelimab followed by thoracic radiotherapy achieved the progression-free survival of 10.1 months and overall survival of 21.4 months, which was longer than chemoimmunotherapy. Another study demonstrated not only thoracic radiotherapy, but also radiotherapy to metastatic lesions could ameliorate survival. Therefore, we supposed that whether radiotherapy to all residual lesions after first-line chemoimmunotherapy could further improve survival for patients with extensive-stage small-cell lung cancer.
CONDITIONS
Official Title
Radiotherapy to All Residual Lesions After Chemoimmunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years old
- ECOG performance status of 0 or 1
- Adequate organ function to tolerate chemotherapy, immunotherapy, and radiotherapy
- Diagnosed with small-cell lung cancer
- Extensive-stage disease confirmed by cranial MRI, chest CT, abdominal ultrasound, bone scan, or PET-CT
- Signed informed consent
You will not qualify if you...
- Younger than 18 or older than 70 years old
- ECOG performance status greater than 1
- Inadequate organ function to tolerate chemotherapy, immunotherapy, and radiotherapy
- Non-small cell lung cancer or other neuroendocrine carcinomas such as carcinoid or large-cell neuroendocrine carcinoma
- Limited-stage disease confirmed by imaging tests
- No signed informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Anhui Provincial Hospital
Hefei, Anhui, China, 230011
Actively Recruiting
Research Team
D
Dong Qian, M.D.
CONTACT
X
Xiao-yang Li, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here